The stock of PainReform Ltd (PRFX) has seen a -23.34% decrease in the past week, with a -35.68% drop in the past month, and a -63.73% decrease in the past quarter. The volatility ratio for the week is 13.70%, and the volatility levels for the past 30 days are at 12.12% for PRFX. The simple moving average for the last 20 days is -30.25% for PRFX’s stock, with a simple moving average of -80.31% for the last 200 days.
Is It Worth Investing in PainReform Ltd (NASDAQ: PRFX) Right Now?
Company’s 36-month beta value is 0.65.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PRFX is 2.70M, and currently, short sellers hold a 1.91% ratio of that floaft. The average trading volume of PRFX on August 07, 2024 was 197.72K shares.
PRFX) stock’s latest price update
PainReform Ltd (NASDAQ: PRFX)’s stock price has gone decline by -4.35 in comparison to its previous close of 0.32, however, the company has experienced a -23.34% decrease in its stock price over the last five trading days. globenewswire.com reported 2024-08-07 that TEL AVIV, Israel, Aug. 07, 2024 (GLOBE NEWSWIRE) — PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced compelling safety data for its lead product candidate, PRF-110. This data, derived from pharmacokinetic (PK) studies in both herniorrhaphy and bunionectomy clinical trials, highlights PRF-110’s promising safety profile, with maximum blood levels (Cmax) recorded at approximately 10% of the FDA-established safety threshold.
PRFX Trading at -40.48% from the 50-Day Moving Average
After a stumble in the market that brought PRFX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.89% of loss for the given period.
Volatility was left at 12.12%, however, over the last 30 days, the volatility rate increased by 13.70%, as shares sank -34.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -54.29% lower at present.
During the last 5 trading sessions, PRFX fell by -20.89%, which changed the moving average for the period of 200-days by -87.35% in comparison to the 20-day moving average, which settled at $0.4362. In addition, PainReform Ltd saw -88.72% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PRFX
Current profitability levels for the company are sitting at:
- -1248279751814168.5 for the present operating margin
- -1666595129258.44 for the gross margin
The net margin for PainReform Ltd stands at -1229555065361918.0. The total capital return value is set at -6.02. Equity return is now at value -233.54, with -158.88 for asset returns.
Based on PainReform Ltd (PRFX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -115.96. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -749.0.
Currently, EBITDA for the company is -9.57 million with net debt to EBITDA at 0.3. When we switch over and look at the enterprise to sales, we see a ratio of -309056341819813.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.61.
Conclusion
In a nutshell, PainReform Ltd (PRFX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
